Evidence map›Paper›PMID 38942027›Full record

ArticleCell host & microbe2024

Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine.

Selene Meza-Perez, Mingyong Liu, Aaron Silva-Sanchez, Casey D Morrow, Peter G Eipers, Elliot J Lefkowitz, Travis Ptacek, Christopher D Scharer, Alexander F Rosenberg, Dave D Hill and 3 more

Abstract read
In one paragraph

Article in Cell host & microbe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Selene Meza-PerezDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mingyong LiuDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Aaron Silva-SanchezDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Casey D MorrowDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Peter G EipersDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Elliot J LefkowitzDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Travis PtacekDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Christopher D ScharerDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Alexander F RosenbergDepartment of Biomedical Informatics and Data Science, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Dave D HillDepartment of Biomedical Informatics and Data Science, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Rebecca C ArendDepartment of Obstetrics and Gynecology, Division of Gynecological Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Michael J GrayDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Troy D RandallDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: troyrandall@uabmc.edu.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Role of microbiota in therapy to ovarian cancerR01CA216234 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2017 to 2021
$2.1M
Multi-parameter, analytic flow cytometerS10OD032296 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2022 to 2022
$464k
NCI NIH HHS P30 CA013148NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA216234NIH HHS S10 OD032296
6 · The paper itself

Abstract

Gut microbiota influence anti-tumor immunity, often by producing immune-modulating metabolites. However, microbes consume a variety of metabolites that may also impact host immune responses. We show that tumors grow unchecked in the omenta of microbe-replete mice due to immunosuppressive Tregs. By contrast, omental tumors in germ-free, neomycin-treated mice or mice colonized with altered Schaedler's flora (ASF) are spontaneously eliminated by CD8

Indexed as

ArginineCD8-Positive T-LymphocytesGastrointestinal MicrobiomeMice, Inbred C57BLOmentumT-Lymphocytes, RegulatoryAnimalsEscherichia coliFemaleMiceNeoplasmsProteobacteriaTOR Serine-Threonine KinasesArgininemTOR protein, mouseTOR Serine-Threonine Kinasesanti-tumor responsesarginine metabolismgut ProteobacteriamTOR pathwayomentumTreg activation

Identifiers

PMID38942027
PMCPMC11245731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.